

27 February 2023

Appendix 4D - Results for Announcement to the Market

Provided below are the Results for Announcement to the Market in accordance with ASX Listing Rule 4.2A and Appendix 4D for EVE Health Group Limited (formerly EVE Investments) and its controlled entities for the period ended 31 December 2022 (the reporting period) compared with the period ended 31 December 2021 (the prior period).

				\$
Revenue from ordinary activities	Up	12.84%	to	1,382,449
Loss from ordinary activities after tax attributable to members	Down	56.15%	to	(1,400,573)
Net loss for the period attributable to members	Down	56.15%	to	(1,400,573)

Net tangible assets per security

	31-Dec-22	31-Dec-21
	\$	\$
Net tangible assets per ordinary security	0.0013	0.0021

Dividends

No dividends were paid, declared or determined during the reporting period.

Details of associates and joint venture entities

	Ownership Interest		Contribution to loss	
	31-Dec-22	31-Dec-21	31-Dec-22	31-Dec-21
	%	%	\$	\$
Omniblend Innovation Pty Ltd	-	37.7%	(248,360)	(258,948)
Naturally Australian Products Inc.	49.0%	49.0%	-	-

Details of entities over which control was gained or lost during the period

On 15 December 2022, the Company disposed of its interest in Omniblend Innovation Pty Ltd. Its contribution to the loss from ordinary activities for the period until the disposal date is disclosed above. A gain on sale of \$223,401 was also recognised in the statement of comprehensive income.

Independent auditor's report

The Consolidated Financial Statements upon which this Appendix 4D is based have been reviewed and the Independent Auditor's Report to the shareholders of EVE Health Group

is included in the financial statements for the half-year ended 31 December 2022 that accompanies this announcement.

Commentary

Commentary on the results for the reporting period is contained within the financial statements for the half-year ended 31 December 2022 that accompanies this announcement.

Authorised for release by Bill Fry, Managing Director.

— ENDS —

For more information, please contact:

Company enquiries

Bill Fry, Managing Director & CEO
EVE Health Group Ltd
+61 8 6465 5500
billf@evehealthgroup.com.au

About EVE Health Group

EVE Health Group, (ASX: EVE) is a leading, vertically integrated producer of branded nutrition, health and wellness products. The Company has global reach and application to fast-growing markets across Australia and New Zealand, Asia Pacific and North America. Our mission is to create high quality, innovative, natural and sustainable health and wellness products that help the wellbeing of consumers and in turn help our people, shareholders and community prosper.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn or Twitter.

eve

HEALTH GROUP

ABN 89 106 523 611

Interim Financial Report
for the six months ended
31 December 2022

Contents

Interim Financial Statements – 31 December 2022

Directors' Report	3
Consolidated Statement of Profit or Loss & Other Comprehensive Income	5
Consolidated Statement of Financial Position	6
Consolidated Statement of Changes in Equity	7
Consolidated Statement of Cash Flows	8
Notes to the Consolidated Financial Statements	9
Directors' Declaration	15
Auditor's Independence Declaration	16
Independent Review Report	17

Director's Report

Interim Financial Statements – 31 December 2022

The Directors of the Group present their report for EVE Health Group Limited for the half-year ended 31 December 2022.

Directors

Directors of the Company at any time during or since the end of the half-year are:

Mr Gregory (Bill) Fry – Managing Director

Mr Alasdair Cooke – Non-Executive Director

Mr Carlos Jin – Non-Executive Director

Mr Rodney Hannington – Non-Executive Director

Mr James Lin – Non-Executive Director (resigned 29 September 2022)

Review of operations

EVE Health Group is an Australian Securities Exchange listed vertically integrated producer of branded health, nutrition and wellness products. The Company has global reach and application to fast-growing markets across Australia and New Zealand, Asia Pacific and North America.

Meluka Australia

Australia

Meluka Australia's (Meluka) strong growth during the period (up 93% on the prior corresponding period) culminated in a record period of Australian sales for its branded range, supported by ongoing consumer interest for its health and wellness products in the digestive health category. The branded beverage range continues to be the leading contributor to Australian revenue, recording the strongest growth of 160% from the prior corresponding period.

The strong sales performance of Meluka's newest probiotic product, P3 Gut Builder Triple Action Postbiotic Tonic, has reinforced the Company's decision to continue to push into the probiotics space. Meluka's first probiotic supplement powder system for improved digestive health was launched in Australia subsequent to period end. The pipeline for future new product development continues, with plans to expand the offering of digestive health products which contain Meluka's proprietary probiotic strain and a variety of effective, functional nutritional ingredients.

In response to ongoing cost increases incurred due to the rising cost of raw materials and commodities from suppliers, along with increases in logistical costs, during July 2022 an analysis of the current market landscape was undertaken, resulting in a price increase being successfully instituted across the Meluka branded products in Australia. As part of the analysis, a review of branded product lines was also undertaken with a view to streamlining product offerings. This will see Meluka reduce the number of organic honey products available, which are a lower gross margin product. Additionally, slower performing probiotic beverage flavours and essential oil products will be phased out in line with the Company's growth strategy to focus on expanding its offering of higher gross margin probiotics products. Going forward, manufacturing is also expected to primarily be conducted through third party manufacturers. These changes are expected to result in reduced inventory holding and production costs.

During the period the company transitioned to fulfilment by a third party distribution provider based in New South Wales for its branded products in Australia. Third party fulfilment will result in increased operating efficiency and allow for scalability as the Company focuses on executing its growth strategy in its home market in expanding its digestive health product offerings.

Director's Report

Interim Financial Statements – 31 December 2022

Other regions

Due to ongoing shipping disruptions, the Company re-evaluated its distribution strategy, shifting focus to growing the Australian market. This resulted in planned slower growth into Japan and postponed expansion plans into North America for the foreseeable future. Revenue across the Company's export regions in North America and Japan was consequently lower during the period. This is in line with expectations as the Company manages reduced advertising and marketing spend. Spend will support product sales of existing stock on hand through current distribution channels, with no current plans to replenish product inventory in export regions for the foreseeable future.

Jenbrook

The Company owns and operates the Robyndale organic tea tree plantation in the Bungawalbin Valley in Northern New South Wales. The heavy rainfall events that were being suffered on the east coast continued to hamper operations during the period. Poor ground conditions prevented mobilisation of machinery until early December. Activities in December concentrated on slashing of plantation areas and cultivation between tree rows to remove weeds. These activities will continue through January and early February. The Company still has adequate inventory of organic tea tree oil products to meet customer demands.

With the continued growth of the Meluka business, the Company considered the need to maintain its tea tree operations as they form an increasingly smaller portion of the Company's overall revenue. As such it engaged Elders to seek expressions of interest for the purchase of both the Jendale and Robyndale properties. The Company is considering the potential sale of these properties as part of a review of its overall business portfolio.

Investments in associates

Naturally Australian Products Inc (NAP) (49% EVE)

Naturally Australian Products, a US distribution business which sells bulk essential oils and extracts to North American businesses, recorded revenue of \$1.2 million in the period, up from \$1.04m in the corresponding period.

Omni Innovation (38% EVE)

During the period the shareholders of Omni Innovation entered into a Share Sale Agreement (Agreement) with Myopharm Limited, an unlisted Australian biotechnology company. The transaction was finalised in December 2022 with EVE receiving \$335,000 cash, being its proportion of the proceeds of the share sale and distribution of net cash held by Omni Innovation at the completion date.

Auditor's Independence Declaration

The auditor's Independence Declaration is set out on page 16 and forms part of the Directors' report for the half year ended 31 December 2022.



Gregory (Bill) Fry
Managing Director
Perth, 24 February 2023

Consolidated Statement of Profit or Loss & Other Comprehensive Income

For the half-year ended 31 December 2022

	Note	31-Dec-22 \$	31-Dec-21 \$
Revenue	6	1,382,449	1,225,149
Costs of goods sold		(711,597)	(707,880)
Gross profit before fair value adjustments		670,852	517,269
Change in fair value of biological assets		-	177,618
Gross profit		670,852	694,887
Other income		43,500	73,319
Professional fees		(117,881)	(88,078)
Employee benefit expense	7	(764,443)	(1,090,334)
Share-based payments		(16,606)	(71,560)
Share of net profit / (loss) of associates accounted for using the equity method	3	(248,360)	(258,948)
Gain / (loss) on sale of associates	3	223,401	-
Impairment expense		(167,393)	(825,059)
Other expenses	7	(1,027,541)	(1,627,542)
Net financial expense		3,898	(1,033)
Loss before income tax		(1,400,573)	(3,194,348)
Income tax (expense) / benefit		-	-
Loss for the period		(1,400,573)	(3,194,348)
Total comprehensive loss attributable to:			
Equity holders of the Company		(1,400,573)	(3,194,348)
Total comprehensive loss for the period		(1,400,573)	(3,194,348)
Loss per share for loss attributable to the ordinary equity holders of the Company:			
Basic and diluted loss per share (cents)		(0.03)	(0.08)

The consolidated statement of profit or loss & other comprehensive income is to be read in conjunction with the accompanying notes.

Consolidated Statement of Financial Position

As at 31 December 2022

	Note	31-Dec-22 \$	30-Jun-22 \$
Assets			
<i>Current Assets</i>			
Cash and cash equivalents		447,516	1,102,423
Trade and other receivables		159,158	250,747
Inventories		1,110,450	1,363,734
Total current assets		1,717,124	2,716,904
<i>Non-current Assets</i>			
Property, plant and equipment	4	4,390,729	4,487,580
Intangibles		-	96,695
Right-of-use assets		16,160	43,689
Equity accounted investments	3	-	359,900
Loans to associates		388,104	368,276
Total non-current assets		4,794,993	5,356,140
Total assets		6,512,117	8,073,044
Liabilities			
<i>Current Liabilities</i>			
Trade and other payables		306,107	647,379
Borrowings		51,975	54,512
Lease liabilities		16,931	41,234
Total current liabilities		375,013	743,125
<i>Non-current Liabilities</i>			
Borrowings		368,804	392,365
Lease liabilities		-	4,283
Total non-current liabilities		368,804	396,648
Total liabilities		743,817	1,139,773
Net assets		5,768,300	6,933,271
Equity			
Issued capital	8	35,834,352	35,615,357
Reserves		431,871	415,265
Accumulated losses		(30,497,923)	(29,097,351)
Total equity attributable to shareholders of the Company		5,768,300	6,933,271

The consolidated statement of financial position is to be read in conjunction with the accompanying notes.

Consolidated Statement of Changes in Equity

For the half-year ended 31 December 2022

	Issued capital	Accumulated losses	Share-based payments	Total
Half-year ended 31 December 2022	\$	\$	\$	\$
Total equity at 1 July 2022	35,615,357	(29,097,351)	415,265	6,933,271
Loss for the period	-	(1,400,573)	-	(1,400,573)
Other comprehensive income	-	-	-	-
Total comprehensive loss for the period	-	(1,400,573)	-	(1,400,573)
Transactions with owners in their capacity as owners:				
Share issue net of issue costs	218,995	-	-	218,995
Share based payment expense	-	-	16,606	16,606
	218,995	-	16,606	235,601
Total equity at 31 December 2022	35,834,352	(30,497,923)	431,871	5,768,300

Half-year ended 31 December 2021

Total equity at 1 July 2021	33,609,712	(23,765,244)	343,323	10,187,791
Loss for the period	-	(3,194,350)	-	(3,194,350)
Other comprehensive income	-	-	-	-
Total comprehensive loss for the period	-	(3,194,350)	-	(3,194,350)
Transactions with owners in their capacity as owners:				
Share based payment expense	-	-	71,561	71,561
	-	-	71,561	71,561
Total equity at 31 December 2021	33,609,712	(26,959,594)	414,884	7,065,002

The consolidated statement of changes in equity is to be read in conjunction with the accompanying notes.

Consolidated Statement of Cash Flows

For the half-year ended 31 December 2022

	31-Dec-22 \$	31-Dec-21 \$
Cash flows from operating activities		
Receipts from customers	1,377,913	1,398,497
Cash paid to suppliers and employees	(2,614,439)	(3,569,109)
Interest received	-	1,534
Interest paid	(13,089)	(8,866)
Other income received	99,450	72,300
Net cash (used) in operating activities	(1,150,165)	(2,105,644)
Cash flows from investing activities		
Proceeds from disposal of business	334,941	-
Acquisition of property, plant and equipment	(1,632)	(22,424)
Net cash (used) in / provided by investing activities	333,309	(22,424)
Cash flows from financing activities		
Proceeds from the issue of share capital	224,000	-
Payment for share issuance costs	(5,005)	-
Lease payments	(30,948)	(61,059)
Proceeds from borrowings	-	107,277
Repayments of borrowings	(26,098)	(137,417)
Net cash (used) in / provided by financing activities	161,949	(91,199)
Net increase / (decrease) in cash and cash equivalents	(654,907)	(2,219,267)
Cash and cash equivalents at 1 July	1,102,423	3,160,409
Cash and cash equivalents at 31 December	447,516	941,142

The consolidated statement of cash flows is to be read in conjunction with the accompanying notes.

Notes to the Consolidated Financial Statements

For the half-year ended 31 December 2022

1. Basis of preparation of half-year statements

These general purpose financial statements are for the interim half-year reporting period ended 31 December 2022 and have been prepared in accordance with *Accounting Standard AASB 134 Interim Financial Reporting* and the *Corporations Act 2001*.

The financial report does not include all the notes of the type normally included in the annual financial statements. Accordingly, this report is to be read in conjunction with the annual financial statements for the year ended 30 June 2022 and any public announcements made by EVE Health Group Limited during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

2. Significant accounting Policies

The accounting policies applied by the Group in these interim financial statements are the same as those applied by the Group in its financial statements as at and for the year ended 30 June 2022 and corresponding interim reporting period, with addition to those noted below:

Going Concern

The ability of the Company to continue as a going concern is dependent on the Company securing additional funding through the issue of debt, equity or through either partial or 100% disposal of assets within the Company's portfolio.

These conditions indicate a material uncertainty that may cast a significant doubt about the entity's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business. Management believes there are sufficient funds to meet the entity's working capital requirements as at the date of this report.

The financial statements have been prepared on the basis that the entity is a going concern, which contemplates the continuity of normal business activity, realisation of assets and settlement of liabilities in the normal course of business for the following reasons:

- The directors have prepared cash flow projections that support the ability of the entity to continue as a going concern;
- The Company has the ability to draw down on its undrawn \$475,000 financing facility;
- Subsequent to reporting period the Company has entered into a sale agreement of its contract manufacturing division, which if completed would realise cash proceeds of \$150,000 (See note 13);
- The Company has the ability to sell other assets in its portfolio of assets;
- The Company can raise additional funds through equity, which it has been able to complete successfully in the past; and
- The Company also has the ability to reduce its expenditure to conserve cash.

Should the Company not be able to continue as a going concern, it may be required to realise its assets and discharge its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the financial statements and that the financial report does not include any adjustments relating to the recoverability and classification of recorded

Notes to the Consolidated Financial Statements

For the half-year ended 31 December 2022

asset amounts or liabilities that might be necessary should the entity not continue as a going concern.

New, revised, or amending Accounting Standards and Interpretations adopted

The entity has adopted all new, revised, or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the entity.

Standards and Interpretations in issue not yet adopted

The Directors have also reviewed all of the new and revised Standards and Interpretations in issue not yet adopted for the half-year ended 31 December 2022.

There is no material impact of the proposed Standards and Interpretations on the Company.

3. Investments in associates

The Company's investments into both Omni Innovation and Naturally Australia Products LLC ("NAP") are recognised as investments in associates. In the period the Company completed a divestment of its interest in Omni Innovation.

Significant Judgment

The 49% investment in NAP has been deemed to be a joint venture with the other equity holder. Key decisions that impact on NAP effectively require the approval of all of NAP's shareholders and therefore EVE is not in a position to control the investment in its own right.

The Company held only 37.7% of Omni Innovation and was not in a position to control the Company's Board or overall direction, although it did hold significant influence.

	31-Dec-22 \$	30-Jun-22 \$
Investments in associates		
Balance at the beginning of the period	359,900	700,967
Share of losses after income tax	(248,360)	(341,067)
Derecognition of investment in Omni Innovation	(111,540)	-
Balance at the end of the period	-	359,900

During the period, the Company received proceeds from the disposal of its interest in Omni Innovation of \$334,941. The difference between the carrying value of the investment on the date of disposal \$111,540 and the amount received has been recognised as a gain on sale of investment in associate of \$223,401.

	Ownership interest %	Assets \$	Company's share of:		
			Liabilities \$	Revenues \$	Profits / (losses) \$
Omni Innovation	37.70%	-	-	-	(248,360)
Naturally Australian Products	49.00%	432,785	822,872	582,080	(53,789)

Notes to the Consolidated Financial Statements

For the half-year ended 31 December 2022

The Company's \$53,7898 share of losses after income tax in Naturally Australian Products hasn't been taken up as the Company's carrying value of Naturally Australian Products is nil.

Loans to associates

	31-Dec-22 \$	30-Jun-22 \$
Loans to associates		
Balance at the beginning of the period	368,276	352,734
Fair-value change on loan extension	-	(42,918)
Unrealised foreign exchange movement	4,538	29,247
Amortised financial expense	15,290	29,213
Balance at the end of the period	388,104	368,276

Loans to associates have a repayment date of 31 December 2024 and have a nil interest rate and are denominated in USD.

4. Property, plant and equipment

	Freehold land \$	Freehold buildings \$	Bearer assets \$	Furniture & fittings \$	Motor vehicles \$	Plant & equipment \$	Computer equipment \$	Total \$
At 30 June 2022								
Cost	2,783,208	297,697	1,244,562	8,062	104,374	698,525	32,072	5,168,501
Accumulated depreciation	-	(54,264)	(245,844)	(3,895)	(30,338)	(328,365)	(18,215)	(680,921)
Net book amount	<u>2,783,208</u>	<u>243,434</u>	<u>998,719</u>	<u>4,167</u>	<u>74,036</u>	<u>370,160</u>	<u>13,857</u>	<u>4,487,580</u>
Half-year ended 31 December 2022								
Opening net book amount	2,783,208	243,434	998,719	4,167	74,036	370,160	13,857	4,487,580
Additions	-	-	-	-	-	5,254	-	5,254
Depreciation charge	-	(7,741)	(41,274)	(760)	(6,997)	(40,212)	(5,121)	(102,105)
Closing Net Book Amount	<u>2,783,208</u>	<u>235,693</u>	<u>957,445</u>	<u>3,407</u>	<u>67,039</u>	<u>335,202</u>	<u>8,736</u>	<u>4,390,729</u>
At 31 December 2022								
Cost or fair value	2,783,208	297,697	1,244,562	8,062	104,374	703,779	32,072	5,173,755
Accumulated depreciation	-	(62,005)	(287,118)	(4,655)	(37,335)	(368,577)	(23,336)	(783,026)
Net book amount	<u>2,783,208</u>	<u>235,693</u>	<u>957,445</u>	<u>3,407</u>	<u>67,039</u>	<u>335,202</u>	<u>8,736</u>	<u>4,390,729</u>

Notes to the Consolidated Financial Statements

For the half-year ended 31 December 2022

5. Segment reporting

The Company's Board receives segment information across three reportable business segments, Jenbrook, Meluka and Investment.

Period ended 31 December 2022	Jenbrook \$	Meluka \$	Investment \$	Unallocated \$	Consolidated \$
Total segment revenue	191,502	1,190,947	-	-	1,382,449
Segment net gain / (loss) after tax	(190,093)	(501,758)	(9,669)	(699,053)	(1,400,573)
Segment assets	4,444,932	1,400,250	388,104	278,831	6,512,117
Segment liabilities	449,697	146,625	-	147,495	743,817
Period ended 31 December 2021	Jenbrook \$	Meluka \$	Investment \$	Unallocated \$	Consolidated \$
Total segment revenue	136,609	1,088,540	-	-	1,225,149
Segment net gain / (loss) after tax	(7,586)	(1,042,326)	(287,330)	(1,857,106)	(3,194,348)
Period ended 30 June 2022	Jenbrook \$	Meluka \$	Investment \$	Unallocated \$	Consolidated \$
Segment assets	4,827,644	1,821,419	728,176	695,805	8,073,044
Segment liabilities	572,119	318,322	-	249,332	1,139,773

6. Revenue

	31-Dec-22 \$	31-Dec-21 \$
At a point in time		
Bulk sales	191,502	136,609
Branded product sales	980,512	790,550
Contract manufacturing	210,435	297,990
	1,382,449	1,225,149

Disaggregation of revenue from contracts with customers

The Group derives its revenue from the bulk sale of essential oils, branded consumer product sales and the provision of contract manufacturing services. The transfer of goods is a point in time for all product lines.

Revenue is recognised when or as the Group transfers control of goods or services to a customer at the amount to which the Group expects to be entitled. If the consideration promised includes a variable component, the Group estimates the expected consideration for the estimated impact of the variable component at the point of recognition and re-estimated at every reporting period.

The Group primarily generates revenue from the sale of tea tree oil and essential oils, honey sales and contract manufacturing.

Notes to the Consolidated Financial Statements

For the half-year ended 31 December 2022

Revenue from the sale of these goods is recognised when control over the inventory has transferred to the customer. Control is generally considered to have passed when:

- physical possession and inventory risk is transferred (including via a third-party transport provider);
- payment terms for the sale of goods can be clearly identified through invoices issued to customers; and
- the customer has no practical ability to reject the product where it is within contractually specified limits.

7. Expenses

	31-Dec-22 \$	31-Dec-21 \$
Employee benefit expense		
Wages	620,223	793,552
Director fees	141,731	278,661
Payroll tax	-	15,963
Fringe benefits tax	2,489	2,158
	764,443	1,090,334
Other expenses		
Corporate costs	38,991	52,525
Premises and insurance	164,866	191,213
Marketing expenses	650,956	1,067,861
Travelling costs	5,133	364
Financing costs	(15,290)	28,383
Depreciation - property, plant and equipment	102,105	117,666
Depreciation - right-to-use assets	27,528	54,636
Amortisation	6,850	6,850
Other operating expenses	46,402	108,044
	1,027,541	1,627,542

8. Issued capital

	31-Dec-22 \$	30-Jun-22 \$
Issued capital	38,130,507	37,906,507
Cost of share issue	(2,296,155)	(2,291,150)
	35,834,352	35,615,357

	31-Dec-22 Shares	30-Jun-22 Shares	31-Dec-22 \$	30-Jun-22 \$
Issues of ordinary shares during the half-year				
Balance at the beginning of the period	5,050,482,664	3,843,141,890	35,615,357	33,609,712
Placement at 0.3 cents per share	-	466,666,667	-	1,400,000
Entitlement offer at 0.1 cents per share	-	740,674,107	-	740,674
Shortfall placement at 0.1 cents per share	224,000,000	-	224,000	-
Capital raising costs	-	-	(5,005)	(135,029)
Balance at the end of the period	5,274,482,664	5,050,482,664	35,834,352	35,615,357

Notes to the Consolidated Financial Statements

For the half-year ended 31 December 2022

9. Dividends

No dividends were declared or paid by the Company.

10. Related parties

Transactions with the related parties are consistent with those disclosed in the 30 June 2022 financial report.

11. Capital and other commitments

There were no capital or other commitments at reporting date.

12. Contingent assets and liabilities

There are no identified contingent assets or liabilities as at reporting date.

13. Events occurring after the reporting period

In February 2023, the Company entered into an agreement to dispose of its contract manufacturing division for cash proceeds of \$150,000.

Other than those disclosed above, there are no matters or circumstances have arisen since the end of the financial period which significantly affected or may significantly affect the operations, results or the state of affairs of the entity in future financial years.

Directors' Declaration

For the half-year ended 31 December 2022

- 1 In the opinion of the directors of EVE Health Group Limited:
 - a. The financial statements and notes set out on pages 5 to 14 are in accordance with the Corporations Act 2001, including:
 - i. Giving a true and fair view of the entity's financial position as at 31 December 2022 and of its performance for the half-year ended on that date; and
 - ii. Complying with AASB 134 Interim Financial Reporting, the *Corporations Regulations 2001* and other mandatory professional reporting requirements; and
 - b. there are reasonable grounds to believe that EVE Health Group Limited will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the directors.



Gregory (Bill) Fry
Managing Director
Perth, 24 February 2023

Auditor's Independence Declaration

For the half-year ended 31 December 2022



Tel: +61 8 6382 4600
Fax: +61 8 6382 4601
www.bdo.com.au

Level 9, Mia Yellagonga Tower 2
5 Spring Street
Perth WA 6000
PO Box 700 West Perth WA 6872
Australia

DECLARATION OF INDEPENDENCE BY ASHLEIGH WOODLEY TO THE DIRECTORS OF EVE HEALTH GROUP LIMITED

As lead auditor for the review of EVE Health Group Limited for the half-year ended 31 December 2022, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
2. No contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of EVE Health Group Limited and the entities it controlled during the period.

A handwritten signature in black ink, appearing to read 'Ashleigh Woodley', is written over a light blue horizontal line.

Ashleigh Woodley
Director

BDO Audit (WA) Pty Ltd
Perth, 24 February 2023

BDO Audit (WA) Pty Ltd ABN 79 112 284 787 is a member of a national association of independent entities which are all members of BDO Australia Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO Audit (WA) Pty Ltd and BDO Australia Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation.

Independent Audit Report

For the half-year ended 31 December 2022



Tel: +61 8 6382 4600
Fax: +61 8 6382 4601
www.bdo.com.au

Level 9, Mia Yellagonga Tower 2
5 Spring Street
Perth WA 6000
PO Box 700 West Perth WA 6872
Australia

INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of EVE Health Group Limited

Report on the Half-Year Financial Report

Conclusion

We have reviewed the half-year financial report of EVE Health Group Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2022, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

- (i) Giving a true and fair view of the Group's financial position as at 31 December 2022 and of its financial performance for the half-year ended on that date; and
- (ii) Complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be the same terms if given to the directors as at the time of this auditor's review report.

Material uncertainty relating to going concern

We draw attention to Note 2 in the financial report which describes the events and/or conditions which give rise to the existence of a material uncertainty that may cast significant doubt about the Group's ability to continue as a going concern and therefore the Group may be unable to realise its assets and discharge its liabilities in the normal course of business. Our conclusion is not modified in respect of this matter.

BDO Audit (WA) Pty Ltd ABN 79 112 284 787 is a member of a national association of independent entities which are all members of BDO Australia Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO Audit (WA) Pty Ltd and BDO Australia Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation.

Independent Audit Report

For the half-year ended 31 December 2022



Responsibility of the directors for the financial report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's responsibility for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2022 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 Interim Financial Reporting and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BDO Audit (WA) Pty Ltd

A handwritten signature in black ink, appearing to read 'Ashleigh Woodley', is written over the BDO logo.

Ashleigh Woodley

Director

Perth, 24 February 2023